NR3C2 and heart failure: MR antagonists have proven benefit for patients with all cause heart failure, with heart failure post-MI and in patients with moderate heart failure, and show potential for patients with heart failure with preserved ejection fraction (HFpEF) (Pitt et al., 1999; Pitt et al., 2003; Markowitz et al., 2012; Miller and Howlett, 2015).